Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.
- 1Digbi Health, Mountain View, CA, United States.
Abstract
Gastrointestinal (GI) adverse events, such as nausea, vomiting, diarrhea, and constipation, remain a dominant barrier to the sustained use of GLP-1 receptor agonists (GLP-1 RAs), driving discontinuation independently of the drug's metabolic benefits. Two host-side biological systems have been independently established as determinants of this variability. The first is host genetics, anchored by a 2026 genome-wide association study in which GLP1R variants predicted both weight-loss efficacy and nausea or vomiting risk, while a GIPR signal for vomiting was restricted to tirzepatide users. The second system is the gut microbiome, which regulates endogenous GLP-1 secretion through short-chain fatty acid and bile acid signaling and is itself reshaped by GLP-1 RA exposure. Pharmacomicrobiomics integrates host genetic and microbiome data to explain drug response. In the literature surveyed for this review, these two determinants are consistently examined in parallel rather than jointly: we did not identify a study, in GLP-1 RA therapy or in another drug class, that fit a 'host-genotype-by-microbiome' interaction model against a drug tolerability outcome. Published methodological studies have suggested why such a study would be challenging: both interaction detection and the measurement unreliability associated with single-timepoint microbiome profiling impose substantial sample size penalties. This review summarizes what host genetics and the microbiome individually do and do not explain about GLP-1 RA tolerability, and describes the study design features, paired genotyping, repeat-sample metagenomics, and prospective symptom capture that a future joint analysis would require.
Related
- Microbial dysbiosis and treatment-related gastrointestinal adverse events in locoregionally advanced nasopharyngeal carcinoma: an exploratory study of the oral and gut microbiome
- Microbiome-driven precision psychiatry: integrating multi-omics, artificial intelligence, and personalized interventions along the gut-brain axis
- Integrating multi-omics technologies to decipher microbiome functions
- High efficacy and tolerability of daratumumab-based regimens in first-line treatment of patients with immunoglobulin light-chain amyloidosis: a real-world evidence analysis
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
BibTeX
@article{kumbhare2026pharmacomicrobiomics,
title = {{Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.}},
author = {Shreyas V Kumbhare and Inti Pedroso and Ranjan Sinha and Daniel E Almonacid},
journal = {Frontiers in microbiomes},
year = {2026},
month = oct,
doi = {10.3389/frmbi.2026.2016564},
url = {https://europepmc.org/article/MED/43011784},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pharmacomicrobiomics of GLP-1 receptor agonist gastrointestinal tolerability: integrating host genetics and the gut microbiome.
AU - Shreyas V Kumbhare
AU - Inti Pedroso
AU - Ranjan Sinha
AU - Daniel E Almonacid
PY - 2026
DA - 2026/10/27
JO - Frontiers in microbiomes
DO - 10.3389/frmbi.2026.2016564
UR - https://europepmc.org/article/MED/43011784
AB - Gastrointestinal (GI) adverse events, such as nausea, vomiting, diarrhea, and constipation, remain a dominant barrier to the sustained use of GLP-1 receptor agonists (GLP-1 RAs), driving discontinuation independently of the drug's metabolic benefits. Two host-side biological systems have been independently established as determinants of this variability. The first is host genetics, anchored by a 2026 genome-wide association study in which GLP1R variants predicted both weight-loss efficacy and nausea or vomiting risk, while a GIPR signal for vomiting was restricted to tirzepatide users. The second system is the gut microbiome, which regulates endogenous GLP-1 secretion through short-chain fatty acid and bile acid signaling and is itself reshaped by GLP-1 RA exposure. Pharmacomicrobiomics integrates host genetic and microbiome data to explain drug response. In the literature surveyed for this review, these two determinants are consistently examined in parallel rather than jointly: we did not identify a study, in GLP-1 RA therapy or in another drug class, that fit a 'host-genotype-by-microbiome' interaction model against a drug tolerability outcome. Published methodological studies have suggested why such a study would be challenging: both interaction detection and the measurement unreliability associated with single-timepoint microbiome profiling impose substantial sample size penalties. This review summarizes what host genetics and the microbiome individually do and do not explain about GLP-1 RA tolerability, and describes the study design features, paired genotyping, repeat-sample metagenomics, and prospective symptom capture that a future joint analysis would require.
SN - 2813-4338
ER -